Claire J Cochrane1, Klaus P Ebmeier. 1. Division of Clinical Neurology and Oxford Centre for Functional MRI of the Brain, Nuffield Department of Clinical Neurosciences, University of Oxford, UK. claire.cochrane@ndcn.ox.ac.uk
Abstract
OBJECTIVES: We performed a systematic review to assess alterations in measures of diffusion tensor imaging (DTI) in parkinsonian syndromes, exploring the potential role of DTI in diagnosis and as a candidate biomarker. METHODS: We searched EMBASE and Medline databases for DTI studies comparing parkinsonian syndromes or related dementias with controls or another defined parkinsonian syndrome. Key details for each study regarding participants, imaging methods, and results were extracted. Estimates were pooled, where appropriate, by random-effects meta-analysis. RESULTS: Of 333 results, we identified 43 studies suitable for inclusion (958 patients, 764 controls). DTI measures detected alterations in all parkinsonian syndromes, with distribution varying differentially with disease type. Nine studies were included in a meta-analysis of the substantia nigra in Parkinson disease. A notable effect size was found for lowered fractional anisotropy in the substantia nigra for patients with Parkinson disease vs controls (-0.639, 95% confidence interval -0.860 to -0.417, p < 0.0001). CONCLUSION: DTI may be a promising biomarker in parkinsonian syndromes and have a future role in differential diagnosis. Larger cohort studies are required to investigate some encouraging preliminary findings. Given the complexity of the parkinsonian syndromes, it is likely that any potential DTI biomarker would be used in combination with other relevant biomarkers.
OBJECTIVES: We performed a systematic review to assess alterations in measures of diffusion tensor imaging (DTI) in parkinsonian syndromes, exploring the potential role of DTI in diagnosis and as a candidate biomarker. METHODS: We searched EMBASE and Medline databases for DTI studies comparing parkinsonian syndromes or related dementias with controls or another defined parkinsonian syndrome. Key details for each study regarding participants, imaging methods, and results were extracted. Estimates were pooled, where appropriate, by random-effects meta-analysis. RESULTS: Of 333 results, we identified 43 studies suitable for inclusion (958 patients, 764 controls). DTI measures detected alterations in all parkinsonian syndromes, with distribution varying differentially with disease type. Nine studies were included in a meta-analysis of the substantia nigra in Parkinson disease. A notable effect size was found for lowered fractional anisotropy in the substantia nigra for patients with Parkinson disease vs controls (-0.639, 95% confidence interval -0.860 to -0.417, p < 0.0001). CONCLUSION: DTI may be a promising biomarker in parkinsonian syndromes and have a future role in differential diagnosis. Larger cohort studies are required to investigate some encouraging preliminary findings. Given the complexity of the parkinsonian syndromes, it is likely that any potential DTI biomarker would be used in combination with other relevant biomarkers.
Authors: D E Vaillancourt; M B Spraker; J Prodoehl; I Abraham; D M Corcos; X J Zhou; C L Comella; D M Little Journal: Neurology Date: 2009-01-07 Impact factor: 9.910
Authors: L-L Chan; H Rumpel; K Yap; E Lee; H-V Loo; G-L Ho; S Fook-Chong; Y Yuen; E-K Tan Journal: J Neurol Neurosurg Psychiatry Date: 2007-07-05 Impact factor: 10.154
Authors: Mariese A Hely; Wayne G J Reid; Michael A Adena; Glenda M Halliday; John G L Morris Journal: Mov Disord Date: 2008-04-30 Impact factor: 10.338
Authors: Michael D Boska; Khader M Hasan; Danette Kibuule; Rebecca Banerjee; Erin McIntyre; Jay A Nelson; Theresa Hahn; Howard E Gendelman; R Lee Mosley Journal: Neurobiol Dis Date: 2007-03-06 Impact factor: 5.996
Authors: Michael J Firbank; Andrew M Blamire; Mani S Krishnan; Andrew Teodorczuk; Philip English; Anil Gholkar; Roger M Harrison; John T O'Brien Journal: Psychiatry Res Date: 2007-04-03 Impact factor: 3.222
Authors: J J Credle; J L George; J Wills; V Duka; K Shah; Y-C Lee; O Rodriguez; T Simkins; M Winter; D Moechars; T Steckler; J Goudreau; D I Finkelstein; A Sidhu Journal: Cell Death Differ Date: 2014-11-14 Impact factor: 15.828
Authors: Amit Khairnar; Peter Latta; Eva Drazanova; Jana Ruda-Kucerova; Nikoletta Szabó; Anas Arab; Birgit Hutter-Paier; Daniel Havas; Manfred Windisch; Alexandra Sulcova; Zenon Starcuk; Irena Rektorova Journal: Neurotox Res Date: 2015-07-08 Impact factor: 3.911
Authors: Yuko Koshimori; Barbara Segura; Leigh Christopher; Nancy Lobaugh; Sarah Duff-Canning; Romina Mizrahi; Clement Hamani; Anthony E Lang; Kelly Aminian; Sylvain Houle; Antonio P Strafella Journal: Brain Struct Funct Date: 2014-05-13 Impact factor: 3.270
Authors: Christopher W Hess; Edward Ofori; Umer Akbar; Michael S Okun; David E Vaillancourt Journal: Curr Neurol Neurosci Rep Date: 2013-11 Impact factor: 5.081